{"id":859433,"date":"2025-06-11T08:04:15","date_gmt":"2025-06-11T12:04:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/envue-medical-granted-u-s-patent-for-pediatric-feeding-tube-guidance-system\/"},"modified":"2025-06-11T08:04:15","modified_gmt":"2025-06-11T12:04:15","slug":"envue-medical-granted-u-s-patent-for-pediatric-feeding-tube-guidance-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/envue-medical-granted-u-s-patent-for-pediatric-feeding-tube-guidance-system\/","title":{"rendered":"ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System"},"content":{"rendered":"

<\/p>\n

ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System<\/b><\/p>\n

Patent strengthens ENvue\u2019s IP position as it advances toward pediatric regulatory clearance and expanded clinical use<\/i><\/p>\n

TYLER, Texas–(BUSINESS WIRE<\/a>)–NanoVibronix, Inc. (NASDAQ: NAOV)<\/b> (\u201cNanoVibronix\u201d or the \u201cCompany\u201d), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (\u201cENvue Medical\u201d or \u201cENvue\u201d), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled \u201cInsertion Device Positioning Guidance System,\u201d<\/i> further strengthens ENvue Medical\u2019s intellectual property portfolio and reflects the Company\u2019s ongoing commitment to innovation in feeding tube placement technologies.<\/p>\n

\nThis newly granted patent covers ENvue\u2019s proprietary system and is designed to assist clinicians in guiding the insertion of feeding tubes in pediatric patients – a population that presents significant anatomical and procedural challenges. This proprietary system is intended to provide real-time navigational data during tube placement, supporting clinical decision-making and potentially reducing reliance on confirmatory imaging.<\/p>\n

\nIn the United States alone, approximately 400,000 preterm infants and a large population of additional pediatric patients, including those in intensive care, surgical recovery and chronic care undergo feeding tube placement annually.1-4<\/sup> Combined, these high-risk groups account for over 1.5 million procedures per year, representing a single U.S. market opportunity of more than $150 million annually in capital systems and disposables5<\/sup>. ENvue\u2019s newly granted patent strengthens its ability to serve this critical segment with real-time, precision-guided navigation.<\/p>\n

\n\u201cWe believe the addressable market for our pediatric navigation platform is substantial,\u201d said Dr. Doron Besser, CEO of the Company. \u201cAccordingly, this patent reflects our commitment to addressing this market opportunity by developing more precise, real-time enteral access solutions tailored to the needs of vulnerable patient populations. We continue to innovate with the goal of expanding clinical capabilities and meeting unmet needs in the field of enteral access.\u201d<\/p>\n

\nAs part of its broader product development strategy, ENvue Medical is preparing to pursue U.S. Food and Drug Administration (FDA) 510(k) clearance for the pediatric use of its ENvue system. The system is currently FDA-cleared for use in adult patients only.<\/p>\n

\nThe newly patented technology builds on the ENvue Enhanced Navigation (EN) platform, which uses electromagnetic tracking to visualize and confirm feeding tube position in real time – without reliance on blind placement or repeated X-rays.<\/p>\n

About NanoVibronix, Inc.<\/b><\/p>\n

\nNanoVibronix, Inc. (NASDAQ: NAOV) is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the Company focuses on two distinct technology platforms:<\/p>\n